Start: 10 Nov 2021, 14:30
End: 10 Nov 2021, 15:30
Speaker: Professor Tatjana Crnogorac-Jurcevic, Barts Cancer Institute, UK
Speaker: Professor Caroline Dive, Cancer Research UK Manchester Institute, UK
Speaker: Professor Yong-Jie Lu, Queen Mary University of London, UK
Speaker: Professor Nitzan Rosenfeld, Cancer Research UK Cambridge Institute, UK
Early diagnosis and precision medicine are essential to control cancer caused death, but require frequent cancer status testing, which is difficult to achieve using tissue samples. Research has shown that liquid biopsies, such as circulating protein and tumour DNA biomarkers, are effective in facilitating an early diagnosis. This session will cover the different types of liquid biopsies in development, what’s new in the last 12 months and the future perspective, and the current technologies (such as GRAIL). Speakers will critically appraise and challenge existing research, aiming to prompt new thinking in the field. Participants will gain insight into the understanding of the potential roles of liquid biopsy biomarkers for cancer management, and the importance of liquid biopsy in cancer detection and treatment.
This session is supported by Bayer – they have had no input into the content.